BIO (BioProtocol) fluctuates 41.0% in 24 hours: Driven by PEPTAIIgnitionSale oversubscription and trading volume surge
Bitget Pulse2026/05/02 13:35Volatility Brief
In the past 24 hours, BIO price rebounded from a low of $0.03964 to a high of $0.05590, currently trading at $0.05561, with an overall price swing of 41.0%. Trading volume has surged significantly, with a 24-hour turnover exceeding $45 million, at times reaching 25 times the average level; Open Interest (OI) has spiked 43.8%, and the funding rate has turned negative to -0.023%, indicating increasing pressure on shorts.
Brief Analysis of the Move
• Bio Protocol officially launched the PEPTAI Ignition Sale (AI agent project for peptide drugs), exceeding 5.9 times the subscription in just 30 minutes after going live, 20% of the supply was allocated to BIO stakers, incentivizing staking and USDC participation, thus driving active trading.
• Trading volume soared 207%, led by buying momentum (196K USDT within 15 minutes), with open interest rising in tandem. The negative funding rate intensified the short squeeze, resulting in a rapid price surge.
• The DeSci sector rotation has accelerated, while market attention grew due to the upgrade of BioXP and listing rumors on Upbit Korea, pushing turnover up to the $300 million level.
Market View and Outlook
The prevailing community sentiment is bullish, with long positions dominating on X, viewing the current situation as an opportunity for DeSci+AI biotech sector rotation. The target price is $0.048-$0.055, but the risk of a short-term squeeze is high (RSI at 78, indicating overbought conditions); analysts advise caution regarding a potential pullback to the $0.032-$0.037 support zone, and recommend monitoring the progress of the PEPTAI sale and staking data. If the price holds above $0.041, it is advised to maintain long positions.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for information purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Marvell plunges 13%, Lumentum plunges 19%! The second largest tech merger in history triggers sell-off
Marvell announced the acquisition of Lumentum for an enterprise value of $115 billion, making it the second largest deal in the technology industry’s history after the merger of SpaceX and xAI. Upon completion of the transaction, former Marvell shareholders will hold approximately 67% of the merged company, and the deal is expected to be finalized in the first half of 2028. However, as AI-related stocks are currently under pressure, the market is not optimistic about this deal. Both Lumentum and Marvell shares plummeted on Monday as investors are concerned about the limited potential for cost synergies and the uncertainty of regulatory approval.
CITIC Securities: Tech sector turbulence, gold hit by liquidity impact
The decline in CFTC gold fund long positions and SPDR holdings suggests that gold may be experiencing a liquidity shock to supplement margin requirements for tech stocks. Despite capital inflows into US Treasuries for risk aversion causing Treasury yields to fall, this has not managed to stimulate bullish sentiment for gold.
Midterm elections coupled with non-farm payroll data may boost market volatility! Oracle (ORCL.US) leads 17 companies in rushing to issue bonds
Oracle (ORCL.US) leads 17 companies entering the U.S. high-grade bond market, rushing to issue bonds ahead of the U.S. midterm elections.
Crypto prices
More
